MXPA03009278A - Farmacos antiangiogenicos peptidos. - Google Patents

Farmacos antiangiogenicos peptidos.

Info

Publication number
MXPA03009278A
MXPA03009278A MXPA03009278A MXPA03009278A MXPA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A
Authority
MX
Mexico
Prior art keywords
antiangiogenic drugs
peptide
peptide antiangiogenic
angiogenesis
inhibiting
Prior art date
Application number
MXPA03009278A
Other languages
English (en)
Inventor
Fortuna Haviv
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA03009278A publication Critical patent/MXPA03009278A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion expone peptidos que son utiles en la inhibicion de angiogenasis. Tambien se exponen composiciones inhibidoras de angiogenesis y metodos para la inhibicion de angiogenesls en un mamifero.
MXPA03009278A 2001-04-11 2002-04-10 Farmacos antiangiogenicos peptidos. MXPA03009278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,733 US20020183242A1 (en) 2001-04-11 2001-04-11 Peptide antiangiogenic drugs
PCT/US2002/011027 WO2002083065A2 (en) 2001-04-11 2002-04-10 Peptide antiangiogenic drugs

Publications (1)

Publication Number Publication Date
MXPA03009278A true MXPA03009278A (es) 2004-03-10

Family

ID=25262479

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009278A MXPA03009278A (es) 2001-04-11 2002-04-10 Farmacos antiangiogenicos peptidos.

Country Status (10)

Country Link
US (1) US20020183242A1 (es)
EP (1) EP1429796A4 (es)
JP (1) JP2005510452A (es)
AU (1) AU2002303278A1 (es)
BR (1) BR0205983A (es)
CA (1) CA2443733A1 (es)
MX (1) MXPA03009278A (es)
PE (1) PE20021078A1 (es)
UY (1) UY27254A1 (es)
WO (1) WO2002083065A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
KR101373140B1 (ko) * 2005-03-03 2014-03-12 씨오브이엑스 테크놀로지스 아일랜드 리미티드 항-혈관형성 화합물
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
KR20140112566A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
EP2804866B1 (en) 2012-01-18 2016-11-16 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン,インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン,インコーポレイテッド 肝疾患を治療する方法
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200937A (en) * 1988-09-29 1993-04-06 Canon Kabushiki Kaisha Apparatus for and method of recording and/or reproducing information by means of two actuators
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
DE69827223T2 (de) * 1997-03-17 2006-02-02 Northwestern University, Chicago Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen
ES2307337T3 (es) * 1998-05-22 2008-11-16 Abbott Laboratories Medicamentos peptidicos anti-angiogenicos.
DE60025648T2 (de) * 1999-11-22 2006-09-14 Abbott Laboratories, Abbott Park Peptide mit antiangiogener aktivität
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica

Also Published As

Publication number Publication date
EP1429796A4 (en) 2005-01-12
UY27254A1 (es) 2002-11-29
BR0205983A (pt) 2006-05-23
CA2443733A1 (en) 2002-10-24
WO2002083065A2 (en) 2002-10-24
PE20021078A1 (es) 2002-12-18
EP1429796A2 (en) 2004-06-23
US20020183242A1 (en) 2002-12-05
AU2002303278A1 (en) 2002-10-28
JP2005510452A (ja) 2005-04-21
WO2002083065A3 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
MXPA03009278A (es) Farmacos antiangiogenicos peptidos.
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
MY138074A (en) Somatostatin analogues
EP1402001A4 (en) Antimicrobial peptides and compounds
ATE396204T1 (de) Peptide als antiangiogene arzneimittel
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
MY126868A (en) Suspension comprising oxcarbazepine
WO2001058470A3 (en) Methods for enhancing the bioavailability of a drug
GB9929464D0 (en) Complementary peptide ligande generated from the human genome
GB0100196D0 (en) Peptides
HK1050012A1 (en) Peptides having antiangiogenic activity
ZA200700168B (en) Remodeling and glycoconjugation of peptides
EP1385556A4 (en) PEPTIDE CONJUGATES WITH AFFINITY FOR GASTRIN RECEPTORS
GB0104752D0 (en) Pharmaceutical compositions
IL162333A0 (en) Peptides inhibiting prions
IL150458A0 (en) Novel haptotactic peptides
SG142165A1 (en) Biologically active peptides
MY145375A (en) Pharmaceutical composition
GB0109438D0 (en) Peptides
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
MY136343A (en) Peptides for treatment of cancer
IL158411A0 (en) Peptides that inhibit viral infections and compositions containing the same
EP1458736A4 (en) RECOMBINANT RINDER THROMBIN
HK1065782A1 (en) Compositions comprising higher diamondoids and processes for their separation